When administered in combination with the  immunosuppressive drug, mycophenolate mofetil (MMF), and low-dose steroids, the drug therapy, LUPKYNIS® (voclosporin), results in earlier and greater reductions in proteinuria in people with lupus nephritis, (LN) across biopsy classes, races, and ethnicities. High levels of protein in urine can affect kidney function and is a useful biomarker for LN.

In a pooled analysis of Phase 2 and Phase 3 trial data, people with a urine protein creatinine ratio (UPCR – a test that measures the level of protein and creatinine in urine) of ≥2 g/g at baseline treated with LUPKYNIS achieved significantly higher renal response rates after one year than those treated with MMF and low-dose steroids alone, regardless of baseline demographics or clinical characteristics. The therapy exhibited favorable results regardless of sex, race, ethnicity, baseline UPCR, or baseline renal function of the person.

The findings further validate LUPKYNIS as a safe and effective treatment for LN. Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about LUPKYNIS.